GU Cancers 2022 | Real-world outcomes of mRCC in the current IO & TKI era

Neil J. Shah, MBBS, Memorial Sloan Kettering Cancer Center, New York City, NY, provides an overview of real-world clinical outcomes of the use of immuno-oncology (IO) agents and tyrosine kinase inhibitors (TKIs) for the management of US patients with metastatic renal cell carcinoma (mRCC). In this real-world study, longer treatment exposure was noted in patient receiving pembrolizumab + axitinib compared to ipilimumab + nivolumab or TKI monotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.